R&D turbulence at Bristol Myers now includes the end of a $650M alliance and the departure of a top research champion
This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage dr-g after spending $650 million to advance it into the clinic.
https://endpts.com/rd-turbulence-bristol-myers-end-650m-alliance-dragonfly-rupert-vessey-departure/